BACKGROUND: PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation. METHODS: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463). RESULTS: From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype. CONCLUSIONS: Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.
BACKGROUND:PALB21592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB21592delT mutation. METHODS: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463). RESULTS: From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB21592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype. CONCLUSIONS: Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.
Authors: Annika Rökman; Tarja Ikonen; Eija H Seppälä; Nina Nupponen; Ville Autio; Nina Mononen; Joan Bailey-Wilson; Jeffrey Trent; John Carpten; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Olli-P Kallioniemi; Johanna Schleutker Journal: Am J Hum Genet Date: 2002-04-08 Impact factor: 11.025
Authors: Marc Tischkowitz; Nelly Sabbaghian; Anna M Ray; Ethan M Lange; William D Foulkes; Kathleen A Cooney Journal: Prostate Date: 2008-05-01 Impact factor: 4.104
Authors: J Carpten; N Nupponen; S Isaacs; R Sood; C Robbins; J Xu; M Faruque; T Moses; C Ewing; E Gillanders; P Hu; P Bujnovszky; I Makalowska; A Baffoe-Bonnie; D Faith; J Smith; D Stephan; K Wiley; M Brownstein; D Gildea; B Kelly; R Jenkins; G Hostetter; M Matikainen; J Schleutker; K Klinger; T Connors; Y Xiang; Z Wang; A De Marzo; N Papadopoulos; O-P Kallioniemi; R Burk; D Meyers; H Grönberg; P Meltzer; R Silverman; J Bailey-Wilson; P Walsh; W Isaacs; J Trent Journal: Nat Genet Date: 2002-01-22 Impact factor: 38.330
Authors: A Rökman; T Ikonen; N Mononen; V Autio; M P Matikainen; P A Koivisto; T L Tammela; O P Kallioniemi; J Schleutker Journal: Cancer Res Date: 2001-08-15 Impact factor: 12.701
Authors: S V Tavtigian; J Simard; D H Teng; V Abtin; M Baumgard; A Beck; N J Camp; A R Carillo; Y Chen; P Dayananth; M Desrochers; M Dumont; J M Farnham; D Frank; C Frye; S Ghaffari; J S Gupte; R Hu; D Iliev; T Janecki; E N Kort; K E Laity; A Leavitt; G Leblanc; J McArthur-Morrison; A Pederson; B Penn; K T Peterson; J E Reid; S Richards; M Schroeder; R Smith; S C Snyder; B Swedlund; J Swensen; A Thomas; M Tranchant; A M Woodland; F Labrie; M H Skolnick; S Neuhausen; J Rommens; L A Cannon-Albright Journal: Nat Genet Date: 2001-02 Impact factor: 38.330
Authors: Jianfeng Xu; S Lilly Zheng; Akira Komiya; Josyf C Mychaleckyj; Sarah D Isaacs; Jennifer J Hu; David Sterling; Ethan M Lange; Gregory A Hawkins; Aubrey Turner; Charles M Ewing; Dennis A Faith; Jill R Johnson; Hiroyoshi Suzuki; Piroska Bujnovszky; Kathleen E Wiley; Angelo M DeMarzo; G Steven Bova; Baoli Chang; M Craig Hall; David L McCullough; Alan W Partin; Vahan S Kassabian; John D Carpten; Joan E Bailey-Wilson; Jeffrey M Trent; Jill Ohar; Eugene R Bleecker; Patrick C Walsh; William B Isaacs; Deborah A Meyers Journal: Nat Genet Date: 2002-09-16 Impact factor: 38.330
Authors: María J García; Victoria Fernández; Ana Osorio; Alicia Barroso; Gemma Llort; Conxi Lázaro; Ignacio Blanco; Trinidad Caldés; Miguel de la Hoya; Teresa Ramón Y Cajal; Carmen Alonso; María-Isabel Tejada; Carlos San Román; Luis Robles-Díaz; Miguel Urioste; Javier Benítez Journal: Breast Cancer Res Treat Date: 2008-02-27 Impact factor: 4.872
Authors: Xin Yang; Goska Leslie; Alicja Doroszuk; Sandra Schneider; Jamie Allen; Brennan Decker; Alison M Dunning; James Redman; James Scarth; Inga Plaskocinska; Craig Luccarini; Mitul Shah; Karen Pooley; Leila Dorling; Andrew Lee; Muriel A Adank; Julian Adlard; Kristiina Aittomäki; Irene L Andrulis; Peter Ang; Julian Barwell; Jonine L Bernstein; Kristie Bobolis; Åke Borg; Carl Blomqvist; Kathleen B M Claes; Patrick Concannon; Adeline Cuggia; Julie O Culver; Francesca Damiola; Antoine de Pauw; Orland Diez; Jill S Dolinsky; Susan M Domchek; Christoph Engel; D Gareth Evans; Florentia Fostira; Judy Garber; Lisa Golmard; Ellen L Goode; Stephen B Gruber; Eric Hahnen; Christopher Hake; Tuomas Heikkinen; Judith E Hurley; Ramunas Janavicius; Zdenek Kleibl; Petra Kleiblova; Irene Konstantopoulou; Anders Kvist; Holly Laduca; Ann S G Lee; Fabienne Lesueur; Eamonn R Maher; Arto Mannermaa; Siranoush Manoukian; Rachel McFarland; Wendy McKinnon; Alfons Meindl; Kelly Metcalfe; Nur Aishah Mohd Taib; Jukka Moilanen; Katherine L Nathanson; Susan Neuhausen; Pei Sze Ng; Tu Nguyen-Dumont; Sarah M Nielsen; Florian Obermair; Kenneth Offit; Olufunmilayo I Olopade; Laura Ottini; Judith Penkert; Katri Pylkäs; Paolo Radice; Susan J Ramus; Vilius Rudaitis; Lucy Side; Rachel Silva-Smith; Valentina Silvestri; Anne-Bine Skytte; Thomas Slavin; Jana Soukupova; Carlo Tondini; Alison H Trainer; Gary Unzeitig; Lydia Usha; Thomas van Overeem Hansen; James Whitworth; Marie Wood; Cheng Har Yip; Sook-Yee Yoon; Amal Yussuf; George Zogopoulos; David Goldgar; John L Hopper; Georgia Chenevix-Trench; Paul Pharoah; Sophia H L George; Judith Balmaña; Claude Houdayer; Paul James; Zaki El-Haffaf; Hans Ehrencrona; Marketa Janatova; Paolo Peterlongo; Heli Nevanlinna; Rita Schmutzler; Soo-Hwang Teo; Mark Robson; Tuya Pal; Fergus Couch; Jeffrey N Weitzel; Aaron Elliott; Melissa Southey; Robert Winqvist; Douglas F Easton; William D Foulkes; Antonis C Antoniou; Marc Tischkowitz Journal: J Clin Oncol Date: 2019-12-16 Impact factor: 44.544
Authors: Dominika Wokołorczyk; Wojciech Kluźniak; Klaudia Stempa; Bogna Rusak; Tomasz Huzarski; Jacek Gronwald; Katarzyna Gliniewicz; Aniruddh Kashyap; Sylwia Morawska; Tadeusz Dębniak; Anna Jakubowska; Marek Szwiec; Paweł Domagała; Jan Lubiński; Steven A Narod; Mohammad R Akbari; Cezary Cybulski Journal: Br J Cancer Date: 2021-05-18 Impact factor: 7.640
Authors: Liisa M Pelttari; Riikka Nurminen; Alexandra Gylfe; Lauri A Aaltonen; Johanna Schleutker; Heli Nevanlinna Journal: BMC Cancer Date: 2012-11-23 Impact factor: 4.430
Authors: Veda N Giri; Karen E Knudsen; William K Kelly; Heather H Cheng; Kathleen A Cooney; Michael S Cookson; William Dahut; Scott Weissman; Howard R Soule; Daniel P Petrylak; Adam P Dicker; Saud H AlDubayan; Amanda E Toland; Colin C Pritchard; Curtis A Pettaway; Mary B Daly; James L Mohler; J Kellogg Parsons; Peter R Carroll; Robert Pilarski; Amie Blanco; Ashley Woodson; Alanna Rahm; Mary-Ellen Taplin; Thomas J Polascik; Brian T Helfand; Colette Hyatt; Alicia K Morgans; Felix Feng; Michael Mullane; Jacqueline Powers; Raoul Concepcion; Daniel W Lin; Richard Wender; James Ryan Mark; Anthony Costello; Arthur L Burnett; Oliver Sartor; William B Isaacs; Jianfeng Xu; Jeffrey Weitzel; Gerald L Andriole; Himisha Beltran; Alberto Briganti; Lindsey Byrne; Anne Calvaresi; Thenappan Chandrasekar; David Y T Chen; Robert B Den; Albert Dobi; E David Crawford; James Eastham; Scott Eggener; Matthew L Freedman; Marc Garnick; Patrick T Gomella; Nathan Handley; Mark D Hurwitz; Joseph Izes; R Jeffrey Karnes; Costas Lallas; Lucia Languino; Stacy Loeb; Ana Maria Lopez; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark Mann; Patrick Mille; Martin M Miner; Todd Morgan; Jose Moreno; Lorelei Mucci; Ronald E Myers; Sarah M Nielsen; Brock O'Neil; Wayne Pinover; Peter Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Charles Ryan; Howard Sandler; Matthew Schiewer; E Michael D Scott; Brittany Szymaniak; William Tester; Edouard J Trabulsi; Neha Vapiwala; Evan Y Yu; Charnita Zeigler-Johnson; Leonard G Gomella Journal: J Clin Oncol Date: 2020-06-09 Impact factor: 44.544